AR056821A1 - Derivados de piperidina sustituida por heteroarilo - Google Patents
Derivados de piperidina sustituida por heteroariloInfo
- Publication number
- AR056821A1 AR056821A1 ARP060105273A ARP060105273A AR056821A1 AR 056821 A1 AR056821 A1 AR 056821A1 AR P060105273 A ARP060105273 A AR P060105273A AR P060105273 A ARP060105273 A AR P060105273A AR 056821 A1 AR056821 A1 AR 056821A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- optionally substituted
- carbonyl
- dihydro
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
REIVINDICACIoN 1.- Compuestos de formula (I) en la que X es C(R8R9), NR10, O, S, S(O), S(O2); R1 es fenilo opcionalmente sustituido con de 1 a 3 sustituyentes elegidos entre el grupo formado por halogeno, hidroxi, alquilo inferior, hidroxialquilo inferior, fluoralquilo inferior, alcoxi inferior y CN; R2 es hidrogeno o alquilo inferior; R3 y R4 con independencia entre sí son hidrogeno, halogeno, alquilo inferior o alcoxi inferior, o R3 y R4 juntos con =O para formar un grupo carbonilo junto con el átomo de carbono al que están unidos; R5 y R6 con independencia entre sí son hidrogeno, halogeno, alquilo inferior o alcoxi inferior, o R5 y R6 juntos son =O para formar un grupo carbonilo junto con el átomo de carbono al que están unidos; R7 es oxadiazolilo o triazolilo, dichos oxadiazolilo o triazolilo están sustituidos por R11 y opcionalmente sustituidos por R12; R8 y R9 con independencia ente sí son hidrogeno, halogeno, hidroxi, alquilo inferior, alcoxi inferior; o R8 y R9 están unidos entre sí y -R8 -R9- es -(CH2)2-7- para formar un anillo junto con el átomo de carbono al que están unidos; R10 es hidrogeno, alquilo inferior, (alquilo inferior)-carbonilo o alquilsulfonilo inferior; R11 es arilo o heteroarilo elegido entre el grupo formado por piridinilo, pirazinilo, pirimidinilo, piridinil-2-ona, oxadiazolilo,indazolilo, 1,3-dihidro-bencimidazol-2-ona, 1,3-dihidro-indol-2-ona, benzotriazolilo, imidazopiridinilo, triazolpiridinilo, tetrazolpiridinilo, bencimidazolilo, 2-oxo-2,3-dihidro-1H-indol-5-ilo, pirimidin-4-ona, furanilo, tiadiazolilo, pirazolilo, isoxazolilo, pirimidina-2,4-diona, benzooxazin-3-ona, 1,4-dihidro-benzooxazin-2-ona, indolilo, tiofenilo, oxazolilo, benzooxazin-2-ona, 3,4-dihidro-quinazolin-2- ona, piridazinilo, quinoxalinilo, benzotiazolilo, benzotiadiazolilo, naftiridinilo, cinolinilo, 1,4-dihidro-quinoxalina-2,3-diona y 1,2-dihidro-indazol-3-ona, dicho arilo o heteroarilo está opcionalmente sustituido con de 1 a 3 sustituyentes elegidos entre el grupo formado por alquilo inferior, hidroxi, B(OH)2, carboxi-alcoxi inferior, carbamoil-alcoxi inferior, ciano, hidroxialquilo inferior, fluoralquilo inferior, alcoxi inferior, halogeno, S(O2)R13, C(O)R14, NO2, NR15R16, imidazolilo, tetrazolilo, pirrolilo, fenil-alcoxi inferior, [1,3,4]oxadiazol-2-ona, oxadiazolilo, triazolilo e isoxazolilo, dicho imidazolilo está opcionalmente sustituido con alquilo inferior y dicho fenil-alcoxi inferior está opcionalmente sustituido con hidroxi, halogeno, alquilo inferior, alcoxi inferior o fluoralquilo inferior y dicho pirazolilo está opcionalmente sustituido con alquilo inferior y dicho isoxazolilo está opcionalmente sustituido con alquilo inferior; R12 es hidrogeno o alquilo inferior; R13 es alquilo inferior, NR17R18 o fluoralquilo inferior; R14 es OH, NR19R20, alcoxi inferior, alqueniloxi inferior o alquilo inferior; R15 y R16 con independencia entre sí son hidrogeno, alquilo inferior, (alquilo inferior)-carbonilo, alquilo inferior-SO2, (alqueniloxi inferior)-carbonilo, NH2-carbonilo, (alquilo inferior)-NH-carbonilo, (alquilo inferior)2N-carbonilo o fenil-alquilo, dicho fenil-alquilo inferior está opcionalemente sustituido con hidroxi, halogeno, alquilo inferior, alcoxi inferior o fluoralquilo inferior; o NR15R16 es un heterociclilo elegido entre el grupo formado por morfolinilo, tiomorfolinilo, 1,1-dioxo-tiomorfolinilo, piperidinilo, piperidin-2-ona, peperazin-2-ona, 8-oxa-3-aza- biciclo[3.2.1]octilo, piperazinilo, pirrolidinilo, 1,1-dioxo-isotiazolidinilo, pirrolidin-2-ona, imidazolidina-2,4-diona, 2,4-dihidro[1,2,4]triazol-3-ona, pirrolidina-2,5-diona, azetin-2-ona y 1,3-dihidro-imidazol-2-ona, dicho heterociclilo está opcionalmente sustituido con hidroxialquilo inferior o (alquilo inferior)-carbonilo; R17 y R18 con independencia entre sí son hidrogeno, alquilo inferior, hidroxialquilo inferior, alcoxi inferior-alquilo inferior; o NR17R18 es morfolinilo; R19 y R20 con independencia entre sí son hidrogeno, alquilo inferior, cicloalquilo, hidroxialquilo inferior, alcoxi inferior-alquilo inferior, (alquilo inferior)2N-alquilo inferior, piridinil-alquilo inferior o ciano-alquilo inferior; o NR19R20 es un heterociclilo elegido entre el grupo formado por morfolinilo, pirrolidinilo, 8-oxa-3-aza-biciclo[3.2.1]octilo, piperidinilo, piperazinilo, piperazin-2-ona, tiazolidinilo, tiomorfolinilo, 1,3,8-triaza-espiro[4,5]decano-2,4diona y espiro(1-ftalano)- piperidin-4-ilo, dicho heterociclilo está opcionalmente sustituido con hidroxi, (alquilo inferior)-S(O2), alquilo inferior, (alquilo inferior)-carbonilo, carboxi, carbamoílo, alcoxi inferior-carbonilo, ciano, fenilo, piridinilo o alcoxi inferior; y las sales y ésteres farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05111560 | 2005-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056821A1 true AR056821A1 (es) | 2007-10-24 |
Family
ID=37719360
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060105273A AR056821A1 (es) | 2005-12-01 | 2006-11-29 | Derivados de piperidina sustituida por heteroarilo |
Country Status (20)
Country | Link |
---|---|
US (1) | US7645776B2 (es) |
EP (1) | EP1959951B1 (es) |
JP (1) | JP4855478B2 (es) |
KR (1) | KR101135310B1 (es) |
CN (1) | CN101321525B (es) |
AR (1) | AR056821A1 (es) |
AT (1) | ATE452635T1 (es) |
AU (1) | AU2006319247B2 (es) |
BR (1) | BRPI0619086A2 (es) |
CA (1) | CA2630460C (es) |
DE (1) | DE602006011363D1 (es) |
DK (1) | DK1959951T3 (es) |
ES (1) | ES2335698T3 (es) |
NO (1) | NO20082388L (es) |
PL (1) | PL1959951T3 (es) |
PT (1) | PT1959951E (es) |
RU (1) | RU2396269C2 (es) |
TW (1) | TWI358409B (es) |
WO (1) | WO2007063012A1 (es) |
ZA (1) | ZA200804393B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200811137A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators II |
JO3598B1 (ar) * | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
KR100847448B1 (ko) * | 2007-03-22 | 2008-07-21 | 한국화학연구원 | 3-아릴-5-알킬-1,2,4-옥사다이아졸 유도체, 그 제조방법 및이를 포함하는 비만 예방 또는 치료용 조성물 |
KR101140520B1 (ko) * | 2007-06-01 | 2012-04-30 | 에프. 호프만-라 로슈 아게 | 피페리딘-아마이드 유도체 |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
TW201000107A (en) * | 2008-04-09 | 2010-01-01 | Infinity Pharmaceuticals Inc | Inhibitors of fatty acid amide hydrolase |
JP5702293B2 (ja) | 2008-11-10 | 2015-04-15 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atrキナーゼの阻害剤として有用な化合物 |
LT3354650T (lt) | 2008-12-19 | 2022-06-27 | Vertex Pharmaceuticals Incorporated | Junginiai, naudingi kaip atr kinazės inhibitoriai |
WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
ES2493916T3 (es) | 2009-04-07 | 2014-09-12 | Infinity Pharmaceuticals, Inc. | Inhibidores de hidrolasa de amida de ácidos grasos |
CA2816448A1 (en) | 2009-05-20 | 2010-11-25 | Heart Metabolics Limited | Treatment of heart failure with normal ejection fraction |
CN102439523B (zh) | 2009-07-23 | 2015-01-07 | 道康宁公司 | 用于双重图案化的方法和材料 |
RU2569061C2 (ru) | 2010-02-03 | 2015-11-20 | Инфинити Фармасьютикалз, Инк. | Ингибиторы амид-гидролазы жирных кислот |
EP2568984A1 (en) | 2010-05-12 | 2013-03-20 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US9062008B2 (en) | 2010-05-12 | 2015-06-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
RU2012153675A (ru) | 2010-05-12 | 2014-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | Соединения, пригодные в качестве ингибиторов atr киназы |
EP2569287B1 (en) | 2010-05-12 | 2014-07-09 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
WO2011143422A1 (en) | 2010-05-12 | 2011-11-17 | Vertex Pharmaceuticals Incorporated | 2 -aminopyridine derivatives useful as inhibitors of atr kinase |
US8933024B2 (en) | 2010-06-18 | 2015-01-13 | Sanofi | Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases |
NZ605627A (en) | 2010-06-23 | 2015-06-26 | Vertex Pharma | Pyrrolo-pyrazine derivatives useful as inhibitors of atr kinase |
US9624173B2 (en) | 2011-03-08 | 2017-04-18 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
WO2012120055A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120053A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8871790B2 (en) | 2011-03-08 | 2014-10-28 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828994B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
US20170119786A1 (en) | 2011-03-08 | 2017-05-04 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
SI2683244T1 (sl) * | 2011-03-08 | 2017-05-31 | 3-V Biosciences, Inc. | Heterociklični modulatorji sinteze lipidov |
US8901114B2 (en) | 2011-03-08 | 2014-12-02 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
EP2694498B1 (en) | 2011-04-05 | 2016-03-30 | Vertex Pharmaceuticals Incorporated | Aminopyrazine compounds useful as inhibitors of tra kinase |
JP2014517079A (ja) | 2011-06-22 | 2014-07-17 | バーテックス ファーマシューティカルズ インコーポレイテッド | Atrキナーゼ阻害剤として有用な化合物 |
WO2012178124A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
WO2012178123A1 (en) | 2011-06-22 | 2012-12-27 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
WO2013049722A1 (en) | 2011-09-30 | 2013-04-04 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8853217B2 (en) | 2011-09-30 | 2014-10-07 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
ES2751741T3 (es) | 2011-09-30 | 2020-04-01 | Vertex Pharma | Procedimiento para fabricar compuestos útiles como inhibidores de la quinasa ATR |
EP2751088B1 (en) | 2011-09-30 | 2016-04-13 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
JP6162126B2 (ja) | 2011-09-30 | 2017-08-23 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Atr阻害剤による膵臓癌及び非小細胞肺癌の治療 |
EP2776419B1 (en) | 2011-11-09 | 2016-05-11 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
EP2776429A1 (en) | 2011-11-09 | 2014-09-17 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
US8841337B2 (en) | 2011-11-09 | 2014-09-23 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US8846917B2 (en) | 2011-11-09 | 2014-09-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
WO2013071093A1 (en) | 2011-11-09 | 2013-05-16 | Vertex Pharmaceuticals Incorporated | Pyrazine compounds useful as inhibitors of atr kinase |
SI2833973T1 (en) | 2012-04-05 | 2018-04-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase and their combination therapy |
NZ703162A (en) | 2012-07-03 | 2017-05-26 | 3-V Biosciences Inc | Heterocyclic modulators of lipid synthesis |
EP2904406B1 (en) | 2012-10-04 | 2018-03-21 | Vertex Pharmaceuticals Incorporated | Method for measuring atr inhibition mediated increases in dna damage |
US8912198B2 (en) | 2012-10-16 | 2014-12-16 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
CA2892608C (en) | 2012-12-07 | 2021-10-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of atr kinase |
KR20150096794A (ko) | 2012-12-21 | 2015-08-25 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 저해제로서의 신규한 헤테로사이클릭 화합물 |
US9663519B2 (en) | 2013-03-15 | 2017-05-30 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
US9636328B2 (en) | 2013-06-21 | 2017-05-02 | Zenith Epigenetics Ltd. | Substituted bicyclic compounds as bromodomain inhibitors |
CN109939113B (zh) | 2013-06-21 | 2022-02-15 | 恒翼生物医药科技(上海)有限公司 | 双环溴结构域抑制剂 |
CA2919948C (en) | 2013-07-31 | 2020-07-21 | Zenith Epigenetics Corp. | Novel quinazolinones as bromodomain inhibitors |
SG10201804791UA (en) | 2013-12-06 | 2018-07-30 | Vertex Pharma | 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof |
CA2934251C (en) | 2013-12-20 | 2024-01-02 | 3-V Biosciences, Inc. | A combination of heterocyclic modulators of lipid synthesis and chemotherapeutic drugs in treatment of cancer |
PT3152212T (pt) | 2014-06-05 | 2020-03-13 | Vertex Pharma | Derivados radiomarcados de um composto de 2-amino-6-fluoro-n-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útil como inibidor de atr quinase, preparação do dito composto e diferentes formas sólidas do mesmo |
KR20170016498A (ko) | 2014-06-17 | 2017-02-13 | 버텍스 파마슈티칼스 인코포레이티드 | Chk1 및 atr 저해제의 병용물을 사용하는 암의 치료 방법 |
WO2016025816A1 (en) | 2014-08-15 | 2016-02-18 | 3-V Biosciences, Inc. | Fatty acid synthase inhibitor for use in the treatment of drug resistant cancer |
EP3227280B1 (en) | 2014-12-01 | 2019-04-24 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
WO2016087936A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Corp. | Substituted pyridinones as bromodomain inhibitors |
CA2966449A1 (en) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
WO2016149271A1 (en) | 2015-03-19 | 2016-09-22 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
JP7187308B2 (ja) | 2015-09-30 | 2022-12-12 | バーテックス ファーマシューティカルズ インコーポレイテッド | Dna損傷剤とatr阻害剤との組み合わせを使用する、がんを処置するための方法 |
DK3362462T3 (da) | 2015-10-12 | 2021-10-11 | Advanced Cell Diagnostics Inc | In situ-detektion af nukleotidvarianter i prøver med højt støjniveau, og sammensætninger og fremgangsmåder relateret dertil |
BR112018009579A2 (pt) | 2015-11-13 | 2018-11-06 | Basf Se | composto da fórmula i, mistura, composição agroquímica, uso de composto e método de combate a fungos |
EP3373732A1 (en) | 2015-11-13 | 2018-09-19 | Basf Se | Substituted oxadiazoles for combating phytopathogenic fungi |
CA3043308A1 (en) | 2016-11-11 | 2018-05-17 | 3-V Biosciences, Inc. | Heterocyclic modulators of lipid synthesis |
CN113939295A (zh) * | 2019-03-20 | 2022-01-14 | 金翅雀生物公司 | 哒嗪酮及其使用方法 |
MX2023012894A (es) | 2021-05-04 | 2024-01-12 | 2N Pharma Aps | Derivados del diazepano, procesos para su preparacion y usos de los mismos para la mejora, prevencion y/o tratamiento de enfermedades mentales y neurologicas. |
WO2023285349A1 (en) * | 2021-07-12 | 2023-01-19 | 2N Pharma Aps | Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5196418A (en) * | 1992-02-14 | 1993-03-23 | Board Of Supervisors, Louisiana State University Agricultural & Mechanical College | Hemicholinium lipids and use thereof |
KR980009257A (ko) * | 1996-07-02 | 1998-04-30 | 주상섭 | 2-히드록시프로피온산 유도체 및 그의 제조방법 |
US6207665B1 (en) * | 1997-06-12 | 2001-03-27 | Schering Aktiengesellschaft | Piperazine derivatives and their use as anti-inflammatory agents |
AU4167099A (en) * | 1998-06-19 | 2000-01-05 | Nissan Chemical Industries Ltd. | Heterocyclic compounds as hypoglycemic agents |
JP2001031652A (ja) * | 1998-06-19 | 2001-02-06 | Nissan Chem Ind Ltd | 六員環複素環類 |
WO2001034594A1 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
BR0315166A (pt) * | 2002-10-11 | 2005-08-16 | Astrazeneca Ab | Uso de um composto ou de um sal farmaceuticamente aceitável do mesmo, composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, que necessita de tratamento |
-
2006
- 2006-11-22 EP EP06819660A patent/EP1959951B1/en not_active Not-in-force
- 2006-11-22 RU RU2008126398/04A patent/RU2396269C2/ru not_active IP Right Cessation
- 2006-11-22 JP JP2008542722A patent/JP4855478B2/ja not_active Expired - Fee Related
- 2006-11-22 PT PT06819660T patent/PT1959951E/pt unknown
- 2006-11-22 DK DK06819660.9T patent/DK1959951T3/da active
- 2006-11-22 CN CN2006800453448A patent/CN101321525B/zh not_active Expired - Fee Related
- 2006-11-22 BR BRPI0619086-3A patent/BRPI0619086A2/pt not_active IP Right Cessation
- 2006-11-22 AU AU2006319247A patent/AU2006319247B2/en not_active Ceased
- 2006-11-22 CA CA2630460A patent/CA2630460C/en not_active Expired - Fee Related
- 2006-11-22 WO PCT/EP2006/068745 patent/WO2007063012A1/en active Application Filing
- 2006-11-22 DE DE602006011363T patent/DE602006011363D1/de active Active
- 2006-11-22 PL PL06819660T patent/PL1959951T3/pl unknown
- 2006-11-22 KR KR1020087015998A patent/KR101135310B1/ko not_active IP Right Cessation
- 2006-11-22 ES ES06819660T patent/ES2335698T3/es active Active
- 2006-11-22 AT AT06819660T patent/ATE452635T1/de active
- 2006-11-29 AR ARP060105273A patent/AR056821A1/es unknown
- 2006-11-29 US US11/605,904 patent/US7645776B2/en not_active Expired - Fee Related
- 2006-11-29 TW TW095144178A patent/TWI358409B/zh not_active IP Right Cessation
-
2008
- 2008-05-21 ZA ZA200804393A patent/ZA200804393B/xx unknown
- 2008-05-26 NO NO20082388A patent/NO20082388L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
RU2008126398A (ru) | 2010-01-10 |
BRPI0619086A2 (pt) | 2011-09-20 |
TW200804357A (en) | 2008-01-16 |
JP2009517438A (ja) | 2009-04-30 |
AU2006319247B2 (en) | 2010-03-11 |
ZA200804393B (en) | 2009-04-29 |
US20070129544A1 (en) | 2007-06-07 |
ATE452635T1 (de) | 2010-01-15 |
AU2006319247A1 (en) | 2007-06-07 |
TWI358409B (en) | 2012-02-21 |
DE602006011363D1 (de) | 2010-02-04 |
JP4855478B2 (ja) | 2012-01-18 |
CN101321525A (zh) | 2008-12-10 |
EP1959951B1 (en) | 2009-12-23 |
WO2007063012A1 (en) | 2007-06-07 |
EP1959951A1 (en) | 2008-08-27 |
US7645776B2 (en) | 2010-01-12 |
KR20080072097A (ko) | 2008-08-05 |
RU2396269C2 (ru) | 2010-08-10 |
AU2006319247A8 (en) | 2008-07-17 |
CA2630460A1 (en) | 2007-06-07 |
ES2335698T3 (es) | 2010-03-31 |
CA2630460C (en) | 2013-01-08 |
CN101321525B (zh) | 2013-01-30 |
DK1959951T3 (da) | 2010-03-01 |
KR101135310B1 (ko) | 2012-04-12 |
NO20082388L (no) | 2008-08-26 |
PL1959951T3 (pl) | 2010-06-30 |
PT1959951E (pt) | 2010-03-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056821A1 (es) | Derivados de piperidina sustituida por heteroarilo | |
RU2503676C2 (ru) | Пирролопиразиновые ингибиторы киназы | |
AR035401A1 (es) | El uso de compuestos derivados de feniletenilo y feniletinilo; compuestos derivados de feniletinilo; compuestos derivados de feniletenilo; un procedimiento para la elaboracion de los mismos; y medicamentos que los contienen | |
JP2009538896A5 (es) | ||
RU2003106193A (ru) | Способ лечения аллергий с использованием замещенных пиразолов | |
AR053406A1 (es) | Derivados de piperidina como inhibidores de renina. composiciones farmaceuticas | |
ES2409109T3 (es) | Derivados de pirimidina- y triazina-sulfonamida como inhibidores del receptor de la bradiquinina b1 (b1r) para el tratamiento del dolor | |
RU2405771C2 (ru) | Гетероциклические замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 | |
RU2005117383A (ru) | Производные фенилаланина в качестве ингибиторов дипептидилпептидазы для лечения или профилактики диабета | |
PE20040265A1 (es) | Compuestos de quinazolina utiles en terapia | |
JP2011516512A5 (ja) | 新規な置換スピロ[シクロアルキル−1,3'−インドール]−2'(1'H)−オン誘導体およびp38マイトジェン活性化タンパク質キナーゼ阻害剤としてのそれらの使用 | |
IL277579B (en) | Piperidinone derivatives as mdm2 inhibitors for cancer therapy | |
PT2066659E (pt) | Derivados de sulfonamida substituídos | |
CA2705405A1 (en) | New compounds | |
ES2319642T3 (es) | Derivados 1,4-di-piperidina-4-il-piperazina sustituidos y su uso como antagonistas de la neuroquinina. | |
RU2007133655A (ru) | Замещенные бис-арильные и гетероарильные соединения в качестве селективных антагонистов 5нт2а | |
IL216247A (en) | Tetrahydrobenzazepine-conjugated and terroyl-containing and used to prevent the reabsorption of norepinephrine, dopamine and serotonin | |
JP2013526536A5 (es) | ||
RU2003107016A (ru) | Замещенные пиразолы | |
PE20090816A1 (es) | Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3 | |
AR076562A1 (es) | Derivados de ciclopenta (c) pirrol-2- carboxilatos, su preparacion y su aplicacion en terapeutica | |
AR063529A1 (es) | Compuestos de pirazolina | |
JP2010524984A5 (es) | ||
PE20080543A1 (es) | Nuevos derivados de fenilo, piridina y quinolina | |
PE20051047A1 (es) | COMPUESTOS [1,2,4] TRIAZOL [4,3-b]PIRIDAZIN-3-ONA COMO MODULADORES DE RECEPTOR CANABINOIDE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |